

Germline and somatic genetics of osteosarcoma “con therapy

Nature Reviews Endocrinology

13, 480-491

DOI: [10.1038/nrendo.2017.16](https://doi.org/10.1038/nrendo.2017.16)

Citation Report

#	ARTICLE	IF	CITATIONS
1	S-phase kinase-associated protein 2 promotes cell growth and motility in osteosarcoma cells. <i>Cell Cycle</i> , 2017, 16, 1547-1555.	1.3	18
2	Is the osteosarcoma genome targetable?. <i>Nature Reviews Endocrinology</i> , 2017, 13, 506-508.	4.3	16
3	miR-216a inhibits osteosarcoma cell proliferation, invasion and metastasis by targeting CDK14. <i>Cell Death and Disease</i> , 2017, 8, e3103-e3103.	2.7	74
4	Role of Epithelial Cell Transforming Sequence 2 (ECT2) in Predicting Prognosis of Osteosarcoma. <i>Medical Science Monitor</i> , 2017, 23, 3861-3868.	0.5	13
5	TET2-dependent IL-6 induction mediated by the tumor microenvironment promotes tumor metastasis in osteosarcoma. <i>Oncogene</i> , 2018, 37, 2903-2920.	2.6	48
6	miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6. <i>Molecular Therapy</i> , 2018, 26, 1299-1312.	3.7	85
7	Diagnostic and prognostic implications of serum miR-101 in osteosarcoma. <i>Cancer Biomarkers</i> , 2018, 22, 127-133.	0.8	35
8	ING5 is a Potential Target for Osteosarcoma Therapy. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381876268.	0.8	5
9	LncRNA CBR3-AS1 predicts unfavorable prognosis and promotes tumorigenesis in osteosarcoma. <i>Biomedicine and Pharmacotherapy</i> , 2018, 102, 169-174.	2.5	32
10	Genome-wide association study identifies the <i>GLDC</i> / <i>IL33</i> locus associated with survival of osteosarcoma patients. <i>International Journal of Cancer</i> , 2018, 142, 1594-1601.	2.3	31
11	MicroRNA-432 is downregulated in osteosarcoma and inhibits cell proliferation and invasion by directly targeting metastasis-associated in colon cancer-1. <i>Experimental and Therapeutic Medicine</i> , 2018, 17, 919-926.	0.8	11
12	Biology of Bone and Soft Tissue Sarcoma: From Molecular Features to Clinical Applications. , 2018, , 134-134.		0
13	Clonal dynamics in osteosarcoma defined by RGB marking. <i>Nature Communications</i> , 2018, 9, 3994.	5.8	40
14	MicroRNA-935 Inhibits Proliferation and Invasion of Osteosarcoma Cells by Directly Targeting High Mobility Group Box 1. <i>Oncology Research</i> , 2018, 26, 1439-1446.	0.6	12
15	Variants in the 14q32 miRNA cluster are associated with osteosarcoma risk in the Spanish population. <i>Scientific Reports</i> , 2018, 8, 15414.	1.6	7
16	Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 947-961.	1.5	12
17	NKX2-2 Suppresses Osteosarcoma Metastasis and Proliferation by Downregulating Multiple Target Genes. <i>Journal of Cancer</i> , 2018, 9, 3067-3077.	1.2	11
18	TIMP3 Overexpression Improves the Sensitivity of Osteosarcoma to Cisplatin by Reducing IL-6 Production. <i>Frontiers in Genetics</i> , 2018, 9, 135.	1.1	11

#	ARTICLE	IF	CITATIONS
19	Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives. <i>Biomedicines</i> , 2018, 6, 19.	1.4	15
20	Theabrownin triggers <sc>DNA</sc> damage to suppress human osteosarcoma U2<sc>OS</sc> cells by activating p53 signalling pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 4423-4436.	1.6	36
21	Serum Antibodies Against Simian Virus 40 Large T Antigen, the Viral Oncoprotein, in Osteosarcoma Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 64.	1.8	6
22	HOXA11-AS; a novel regulator in human cancer proliferation and metastasis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4387-4393.	1.0	43
23	MicroRNAâ€™2682â€™3p inhibits osteosarcoma cell proliferation by targeting CCND2, MMP8 and Myd88. <i>Oncology Letters</i> , 2018, 16, 3359-3364.	0.8	9
24	Circulating miR-215-5p and miR-642a-5p as potential biomarker for diagnosis of osteosarcoma in Mexican population. <i>Human Cell</i> , 2018, 31, 292-299.	1.2	31
25	SNHG16 promotes osteosarcoma progression and enhances cisplatin resistance by sponging miR-16 to upregulate ATG4B expression. <i>Biochemical and Biophysical Research Communications</i> , 2019, 518, 127-133.	1.0	46
26	Downregulation of <i>UBE2T</i> can enhance the radiosensitivity of osteosarcoma <i>in vitro</i> and <i>in vivo</i>. <i>Epigenomics</i> , 2019, 11, 1283-1305.	1.0	9
27	Inhibition of M2-like macrophages by all-trans retinoic acid prevents cancer initiation and stemness in osteosarcoma cells. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 1343-1350.	2.8	59
28	Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. <i>Cancer</i> , 2019, 125, 3514-3525.	2.0	86
29	Exosomal miR-1228 From Cancer-Associated Fibroblasts Promotes Cell Migration and Invasion of Osteosarcoma by Directly Targeting SCAL. <i>Oncology Research</i> , 2019, 27, 979-986.	0.6	66
30	Bone and Softâ€™Tissue Sarcoma Risk in Longâ€™Term Survivors of Hereditary Retinoblastoma Treated With Radiation. <i>Journal of Clinical Oncology</i> , 2019, 37, 3436-3445.	0.8	19
31	Synthesis, Properties, and Characterization of Fieldâ€™s Alloy Nanoparticles and Its Slurry. , 2019, , .		0
32	MicroRNA-99b predicts clinical outcome of osteosarcoma and suppresses tumor cell proliferation, migration and invasion. <i>Diagnostic Pathology</i> , 2019, 14, 117.	0.9	7
33	Integrated analysis of transcriptome-wide m⁶A methylome of osteosarcoma stem cells enriched by chemotherapy. <i>Epigenomics</i> , 2019, 11, 1693-1715.	1.0	73
34	Expression and significance of Annexin A3 in the osteosarcoma cell lines HOS and U2OS. <i>Molecular Medicine Reports</i> , 2019, 20, 2583-2590.	1.1	4
35	ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma. <i>Theranostics</i> , 2019, 9, 6334-6353.	4.6	18
36	Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice. <i>BMC Cancer</i> , 2019, 19, 924.	1.1	24

#	ARTICLE	IF	CITATIONS
37	MicroRNA-206 Reduces Osteosarcoma Cell Malignancy <i>In Vitro</i> by Targeting the PAX3-MET Axis. <i>Yonsei Medical Journal</i> , 2019, 60, 163.	0.9	16
38	Targeted transcriptional profiling of the tumor microenvironment reveals lymphocyte exclusion and vascular dysfunction in metastatic osteosarcoma. <i>OncImmunity</i> , 2019, 8, e1629779.	2.1	7
39	A four serum-miRNA panel serves as a potential diagnostic biomarker of osteosarcoma. <i>International Journal of Clinical Oncology</i> , 2019, 24, 976-982.	1.0	26
40	Role of autophagy in osteosarcoma. <i>Journal of Bone Oncology</i> , 2019, 16, 100235.	1.0	53
41	Endoplasmic reticulum protein 29 (ERp29) as a novel prognostic marker and tumor suppressor in osteosarcoma. <i>Journal of Bone Oncology</i> , 2019, 16, 100233.	1.0	10
42	MicroRNAs in Bone Metastasis. <i>Current Osteoporosis Reports</i> , 2019, 17, 122-128.	1.5	26
43	Overexpression of miR-1258 inhibits cell proliferation by targeting AKT3 in osteosarcoma. <i>Biochemical and Biophysical Research Communications</i> , 2019, 510, 479-486.	1.0	25
44	Pediatric Osteosarcoma of Extremities: A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, e371-e383.	0.3	3
45	Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma. <i>Journal of Immunotherapy</i> , 2019, 42, 321-330.	1.2	31
46	miR-624-5p promoted tumorigenesis and metastasis by suppressing hippo signaling through targeting PTPRB in osteosarcoma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 488.	3.5	39
47	MiR-204-5p promotes apoptosis and inhibits migration of osteosarcoma via targeting EBF2. <i>Biochimie</i> , 2019, 158, 224-232.	1.3	37
48	Advances in Sarcoma Genomics and Therapeutic Management. , 2019, , 609-621.		0
49	Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis. <i>Cancer Letters</i> , 2019, 440-441, 116-125.	3.2	117
50	2-Bromopalmitate sensitizes osteosarcoma cells to adriamycin-induced apoptosis via the modulation of CHOP. <i>European Journal of Pharmacology</i> , 2019, 844, 204-215.	1.7	14
51	Singe nucleotide polymorphisms in osteosarcoma: Pathogenic effect and prognostic significance. <i>Experimental and Molecular Pathology</i> , 2019, 106, 63-77.	0.9	15
52	Upregulation of long non-coding RNA NNT-AS1 promotes osteosarcoma progression by inhibiting the tumor suppressive miR-320a. <i>Cancer Biology and Therapy</i> , 2019, 20, 413-422.	1.5	28
53	Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone. <i>Journal of Pathology</i> , 2019, 247, 166-176.	2.1	28
54	SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis. <i>Oncogene</i> , 2020, 39, 1049-1062.	2.6	13

#	ARTICLE	IF	CITATIONS
55	Targeting USP9x/SOX2 axis contributes to the anti-osteosarcoma effect of neogambogic acid. <i>Cancer Letters</i> , 2020, 469, 277-286.	3.2	23
56	Common genetic variation and risk of osteosarcoma in a multi-ethnic pediatric and adolescent population. <i>Bone</i> , 2020, 130, 115070.	1.4	22
57	Chlorogenic acid activates ERK1/2 and inhibits proliferation of osteosarcoma cells. <i>Journal of Cellular Physiology</i> , 2020, 235, 3741-3752.	2.0	28
58	Omic approaches to pediatric bone sarcomas. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28072.	0.8	14
59	LncRNA KRAL suppresses cell growth and increases sensitivity to doxorubicin in osteosarcoma cells by sponging microRNAs-141. <i>European Journal of Inflammation</i> , 2020, 18, 205873922095990.	0.2	0
60	Nanoparticle enhanced combination therapy for stem-like progenitors defined by single-cell transcriptomics in chemotherapy-resistant osteosarcoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 196.	7.1	29
61	Multifaceted Functions and Novel Insight Into the Regulatory Role of RNA N6-Methyladenosine Modification in Musculoskeletal Disorders. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 870.	1.8	31
62	Acetylation dependent functions of Rab22a-Neof1 Fusion Protein in Osteosarcoma. <i>Theranostics</i> , 2020, 10, 7747-7757.	4.6	11
63	Combinatorial Nanomedicine Made of Squalenoyl-Gemcitabine and Edelfosine for the Treatment of Osteosarcoma. <i>Cancers</i> , 2020, 12, 1895.	1.7	7
64	Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B. <i>Cancer Letters</i> , 2020, 490, 54-65.	3.2	84
65	Ginsenoside Rg3 Inhibits the Growth of Osteosarcoma and Attenuates Metastasis through the Wnt/ β -Catenin and EMT Signaling Pathway. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-12.	0.5	15
66	Comprehensive metabolomic profiling of osteosarcoma based on UHPLC-HRMS. <i>Metabolomics</i> , 2020, 16, 120.	1.4	12
67	Genetic Predisposition to Solid Pediatric Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 590033.	1.3	31
68	Genomics and the Immune Landscape of Osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1258, 21-36.	0.8	31
69	Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5207.	1.8	119
70	Molecular Biology of Osteosarcoma. <i>Cancers</i> , 2020, 12, 2130.	1.7	198
71	Prognostic Factors in Patients With Osteosarcoma With the Surveillance, Epidemiology, and End Results Database. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382094770.	0.8	9
72	miR-766-3p Targeting BCL9L Suppressed Tumorigenesis, Epithelial-Mesenchymal Transition, and Metastasis Through the β -Catenin Signaling Pathway in Osteosarcoma Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 594135.	1.8	11

#	ARTICLE	IF	CITATIONS
73	LncRNA ADAMTS9-AS2 in osteosarcoma inhibits cell proliferation and enhances paclitaxel sensitivity by suppressing microRNA-130a-5p. <i>European Journal of Inflammation</i> , 2020, 18, 205873922093456.	0.2	3
74	Proanthocyanidin B2 inhibits proliferation and induces apoptosis of osteosarcoma cells by suppressing the PI3K/AKT pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 11960-11971.	1.6	16
75	Systematic screening for potential therapeutic targets in osteosarcoma through a kinome-wide CRISPR-Cas9 library. <i>Cancer Biology and Medicine</i> , 2020, 17, 782-794.	1.4	8
77	The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor Growth. <i>Cancers</i> , 2020, 12, 3847.	1.7	26
78	LncRNA SNHG3, a potential oncogene in human cancers. <i>Cancer Cell International</i> , 2020, 20, 536.	1.8	41
79	Functionalization of Ti substrate with pH-responsive naringin@ZnO nanoparticles for the reconstruction of large bony after osteosarcoma resection. <i>Journal of Biomedical Materials Research - Part A</i> , 2020, 108, 2190-2205.	2.1	24
80	The crucial p53-dependent oncogenic role of JAB1 in osteosarcoma in vivo. <i>Oncogene</i> , 2020, 39, 4581-4591.	2.6	22
81	The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice. <i>Cancers</i> , 2020, 12, 1207.	1.7	12
82	LncRNA PLAC 2 Is Downregulated in Osteosarcoma and Regulates Cancer Cell Proliferation Through miR-93. <i>Cancer Management and Research</i> , 2020, Volume 12, 3623-3629.	0.9	1
83	Immune-related prognosis biomarkers associated with osteosarcoma microenvironment. <i>Cancer Cell International</i> , 2020, 20, 83.	1.8	45
84	AdipoRon Affects Cell Cycle Progression and Inhibits Proliferation in Human Osteosarcoma Cells. <i>Journal of Oncology</i> , 2020, 2020, 1-12.	0.6	20
85	Prognostic factors in osteosarcoma: A study level meta-analysis and systematic review of current practice. <i>Journal of Bone Oncology</i> , 2020, 21, 100281.	1.0	39
86	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. <i>JAMA Oncology</i> , 2020, 6, 724.	3.4	139
87	Antitumor Effect of miR-1294/Pyruvate Kinase M2 Signaling Cascade in Osteosarcoma Cells. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 1637-1647.	1.0	11
88	Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4659.	1.8	12
89	A comprehensive evaluation of single nucleotide polymorphisms associated with osteosarcoma risk. <i>Medicine (United States)</i> , 2020, 99, e20486.	0.4	3
90	LncRNA FLVCR-AS1 promotes osteosarcoma growth by targeting miR381-3p/CCND1. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 163-172.	1.0	10
91	Gene Prioritization through Consensus Strategy, Enrichment Methodologies Analysis, and Networking for Osteosarcoma Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1053.	1.8	13

#	ARTICLE	IF	CITATIONS
92	Engineering 2D Mesoporous Silica@MXeneâ€Integrated 3Dâ€Printing Scaffolds for Combinatory Osteosarcoma Therapy and NOâ€Augmented Bone Regeneration. <i>Small</i> , 2020, 16, e1906814.	5.2	98
93	A 20â€year long term experience of the Italian Diamondâ€Blackfan Anaemia Registry: <i>RPS</i> and <i>RPL</i> genes, different faces of the same disease?. <i>British Journal of Haematology</i> , 2020, 190, 93-104.	1.2	35
94	Î²-Elemonic acid inhibits the growth of human Osteosarcoma through endoplasmic reticulum (ER) stress-mediated PERK/eIF2Î±/ATF4/CHOP activation and Wnt/Î²-catenin signal suppression. <i>Phytomedicine</i> , 2020, 69, 153183.	2.3	31
95	Key genes with prognostic values in suppression of osteosarcoma metastasis using comprehensive analysis. <i>BMC Cancer</i> , 2020, 20, 65.	1.1	19
96	Knockdown of TBRG4 suppresses proliferation, invasion and promotes apoptosis of osteosarcoma cells by downregulating TGF-Î²1 expression and PI3K/AKT signaling pathway. <i>Archives of Biochemistry and Biophysics</i> , 2020, 686, 108351.	1.4	12
97	Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors. <i>Cells</i> , 2020, 9, 968.	1.8	19
98	The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem. <i>Cells</i> , 2020, 9, 976.	1.8	251
99	LncRNA LINC00588 Suppresses the Progression of Osteosarcoma by Acting as a ceRNA for miRNA-1972. <i>Frontiers in Pharmacology</i> , 2020, 11, 255.	1.6	18
100	Second near-infrared photothermal materials for combinational nanotheranostics. <i>Chemical Society Reviews</i> , 2021, 50, 1111-1137.	18.7	508
101	Insights of Tris(2-pyridylmethyl)amine as anti-tumor agent for osteosarcoma: experimental and in silico studies. <i>Journal of Molecular Structure</i> , 2021, 1228, 129773.	1.8	2
102	Cisplatinâ€resistant osteosarcoma cellâ€derived exosomes confer cisplatin resistance to recipient cells in an exosomal circ_103801â€dependent manner. <i>Cell Biology International</i> , 2021, 45, 858-868.	1.4	39
103	Sex differences in expression of immune elements emerge in children, young adults and mice with osteosarcoma. <i>Biology of Sex Differences</i> , 2021, 12, 5.	1.8	6
104	Systematic profiling of diagnostic and prognostic value of autophagy-related genes for sarcoma patients. <i>BMC Cancer</i> , 2021, 21, 58.	1.1	2
105	Circ_0105346 Knockdown Inhibits Osteosarcoma Development via Regulating miR-1182/WNT7B Axis. <i>Cancer Management and Research</i> , 2021, Volume 13, 521-535.	0.9	3
106	ICT1 Promotes Osteosarcoma Cell Proliferation and Inhibits Apoptosis via STAT3/BCL-2 Pathway. <i>BioMed Research International</i> , 2021, 2021, 1-10.	0.9	3
107	Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 1670-1680.	0.9	10
108	KDM6B-mediated histone demethylation of LDHA promotes lung metastasis of osteosarcoma. <i>Theranostics</i> , 2021, 11, 3868-3881.	4.6	27
109	Precision Medicine in Osteosarcoma: MATCH Trial and Beyond. <i>Cells</i> , 2021, 10, 281.	1.8	5

#	ARTICLE	IF	CITATIONS
110	Ligustilide inhibits the proliferation of human osteoblastoma MG63 cells through the TLR4-ERK pathway. <i>Life Sciences</i> , 2022, 288, 118993.	2.0	2
111	The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis. <i>BMC Cancer</i> , 2021, 21, 202.	1.1	6
113	Cesarean Section Is Associated with an Increased Risk of Acute Lymphoblastic Leukemia and Hepatoblastoma in Children from Minnesota. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 736-742.	1.1	8
114	Osteosarcoma Cell-Derived Small Extracellular Vesicles Enhance Osteoclastogenesis and Bone Resorption Through Transferring MicroRNA-19a-3p. <i>Frontiers in Oncology</i> , 2021, 11, 618662.	1.3	10
115	Protein and Signaling Pathway Responses to rhIL-6 Intervention Before Lobaplatin Treatment in Osteosarcoma Cells. <i>Frontiers in Oncology</i> , 2021, 11, 602712.	1.3	9
116	Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-13.	1.9	13
117	Dog breeds and body conformations with predisposition to osteosarcoma in the UK: a case-control study. <i>Canine Medicine and Genetics</i> , 2021, 8, 2.	1.4	15
118	FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53. <i>Oncogene</i> , 2021, 40, 2785-2802.	2.6	22
119	Review of a new bone tumor therapy strategy based on bifunctional biomaterials. <i>Bone Research</i> , 2021, 9, 18.	5.4	125
120	The relationship between the expression of Ki-67 and the prognosis of osteosarcoma. <i>BMC Cancer</i> , 2021, 21, 210.	1.1	18
121	Circular RNA circSIPA1L1 Contributes to Osteosarcoma Progression Through the miR-411-5p/RAB9A Signaling Pathway. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 642605.	1.8	8
122	lncRNA SNHG16 contributes to osteosarcoma progression by acting as a ceRNA of miR-1285-3p. <i>BMC Cancer</i> , 2021, 21, 355.	1.1	11
123	3D Printed Bioceramic Scaffolds as a Universal Therapeutic Platform for Synergistic Therapy of Osteosarcoma. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 18488-18499.	4.0	31
124	Hyaluronate-Based Self-Stabilized Nanoparticles for Immunosuppression Reversion and Immunochemotherapy in Osteosarcoma Treatment. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 1515-1525.	2.6	15
125	EF24 induces ferroptosis in osteosarcoma cells through HMOX1. <i>Biomedicine and Pharmacotherapy</i> , 2021, 136, 111202.	2.5	85
126	Improving Bioavailability of Hydrophobic Prodrugs through Supramolecular Nanocarriers Based on Recombinant Proteins for Osteosarcoma Treatment. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 11252-11256.	7.2	37
127	Improving Bioavailability of Hydrophobic Prodrugs through Supramolecular Nanocarriers Based on Recombinant Proteins for Osteosarcoma Treatment. <i>Angewandte Chemie</i> , 2021, 133, 11352-11356.	1.6	5
128	The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis. <i>Cancers</i> , 2021, 13, 2478.	1.7	24

#	ARTICLE	IF	CITATIONS
129	Regulatory Role of N6-methyladenosine (m6A) Modification in Osteosarcoma. <i>Frontiers in Oncology</i> , 2021, 11, 683768.	1.3	7
130	Osteosarcoma in One of Identical Twins: Three Cases Report and a Literature Review. <i>Orthopaedic Surgery</i> , 2021, 13, 1443-1451.	0.7	2
131	Construction and Validation of an Autophagy-Related Prognostic Model for Osteosarcoma Patients. <i>Journal of Oncology</i> , 2021, 2021, 1-16.	0.6	2
132	Identification of KIF4A as a pan-cancer diagnostic and prognostic biomarker via bioinformatics analysis and validation in osteosarcoma cell lines. <i>PeerJ</i> , 2021, 9, e11455.	0.9	4
133	Factors Associated with Promoted Proliferation of Osteosarcoma by Peptidylarginine Deiminase 4. <i>BioMed Research International</i> , 2021, 2021, 1-10.	0.9	4
134	A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 699212.	1.8	11
135	3â€²,4â€²-Dihydroxyflavonol Modulates the Cell Cycle in Cancer Cells: Implication as a Potential Combination Drug in Osteosarcoma. <i>Pharmaceuticals</i> , 2021, 14, 640.	1.7	3
136	Innovative Biomaterials for the Treatment of Bone Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8214.	1.8	17
137	Polydatin Induces Differentiation and Radiation Sensitivity in Human Osteosarcoma Cells and Parallel Secretion through Lipid Metabolite Secretion. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-11.	1.9	13
138	Advances in targeted therapy for osteosarcoma based on molecular classification. <i>Pharmacological Research</i> , 2021, 169, 105684.	3.1	25
139	The different biological effects of TMPyP4 and cisplatin in the inflammatory microenvironment of osteosarcoma are attributed to Gâ€²quadruplex. <i>Cell Proliferation</i> , 2021, 54, e13101.	2.4	10
140	Identification of two immune subtypes in osteosarcoma based on immune gene sets. <i>International Immunopharmacology</i> , 2021, 96, 107799.	1.7	8
141	MicroRNA-802 promotes the progression of osteosarcoma through targeting p27 and activating PI3K/AKT pathway. <i>Clinical and Translational Oncology</i> , 2022, 24, 266-275.	1.2	4
142	New drug candidates for osteosarcoma: Drug repurposing based on gene expression signature. <i>Computers in Biology and Medicine</i> , 2021, 134, 104470.	3.9	6
143	Additively manufactured patient-specific prosthesis for tumor reconstruction: Design, process, and properties. <i>PLoS ONE</i> , 2021, 16, e0253786.	1.1	11
144	Pyroptosis, a New Breakthrough in Cancer Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 698811.	1.3	29
145	A deep learningâ€”machine learning fusion approach for the classification of benign, malignant, and intermediate bone tumors. <i>European Radiology</i> , 2022, 32, 1371-1383.	2.3	14
146	Whole-exome sequencing in osteosarcoma with distinct prognosis reveals disparate genetic heterogeneity. <i>Cancer Genetics</i> , 2021, 256-257, 149-157.	0.2	6

#	ARTICLE	IF	CITATIONS
147	Combination of ultrathin micro-patterned MXene and PEDOT: Poly(styrenesulfonate) enables organic electrochemical transistor for amperometric determination of survivin protein in children osteosarcoma. <i>Mikrochimica Acta</i> , 2021, 188, 301.	2.5	6
148	Gold nanorods and nanohydroxyapatite hybrid hydrogel for preventing bone tumor recurrence via postoperative photothermal therapy and bone regeneration promotion. <i>Bioactive Materials</i> , 2021, 6, 2221-2230.	8.6	100
149	The smac mimetic LCL161 targets established pulmonary osteosarcoma metastases in mice. <i>Clinical and Experimental Metastasis</i> , 2021, 38, 441-449.	1.7	3
150	Investigation of inhibition effect of daidzein on osteosarcoma cells based on experimental validation and systematic pharmacology analysis. <i>PeerJ</i> , 2021, 9, e12072.	0.9	3
151	Circ_0084582 Facilitates Cell Growth, Migration, Invasion, and Angiopoiesis in Osteosarcoma via Mediating the miR-485-3p/JAG1 Axis. <i>Frontiers in Genetics</i> , 2021, 12, 690956.	1.1	5
152	hsa_circ_0000006 induces tumorigenesis through miR-361-3p targeting immunoglobulin-like domains protein 1 (LRIG1) in osteosarcoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1242-1242.	0.7	7
153	Circulating Long Non-Coding RNAs as Novel Potential Biomarkers for Osteogenic Sarcoma. <i>Cancers</i> , 2021, 13, 4214.	1.7	10
154	Macrophages loaded with dendrimer-entrapped gold nanoparticles as a theranostic platform for CT imaging-guided combinational therapy of orthotopic osteosarcoma. <i>Chemical Engineering Journal</i> , 2021, 417, 129273.	6.6	11
155	Overexpression of the Ubiquitin Specific Proteases USP43, USP41, USP27x and USP6 in Osteosarcoma Cell Lines: Inhibition of Osteosarcoma Tumor Growth and Lung Metastasis Development by the USP Antagonist PR619. <i>Cells</i> , 2021, 10, 2268.	1.8	16
156	Establishment of an Autophagy-Related Clinical Prognosis Model for Predicting the Overall Survival of Osteosarcoma. <i>BioMed Research International</i> , 2021, 2021, 1-17.	0.9	4
157	Large Scale Identification of Osteosarcoma Pathogenic Genes by Multiple Extreme Learning Machine. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 755511.	1.8	2
158	MicroRNA-545-5p regulates apoptosis, migration and invasion of osteosarcoma by targeting dimethyladenosine transferase 1. <i>Oncology Letters</i> , 2021, 22, 763.	0.8	1
159	Identification of abnormally high expression of POGZ as a new biomarker associated with a poor prognosis in osteosarcoma. <i>European Journal of Histochemistry</i> , 2021, 65, .	0.6	4
160	Circular RNA-Related CeRNA Network and Prognostic Signature for Patients with Osteosarcoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 7527-7541.	0.9	6
161	RCAN1.4 suppresses the osteosarcoma growth and metastasis via interfering with the calcineurin/NFAT signaling pathway. <i>Journal of Bone Oncology</i> , 2021, 30, 100383.	1.0	3
162	Metformin and primary bone cancer risk in Taiwanese patients with type 2 diabetes mellitus. <i>Bone</i> , 2021, 151, 116037.	1.4	6
163	Markers for bone sarcomas. , 2022, , 543-577.		0
164	Molecular pathology of osteosarcoma. , 2022, , 579-590.		1

#	ARTICLE	IF	CITATIONS
165	MUC 15 Promotes Osteosarcoma Cell Proliferation, Migration and Invasion through Livin, MMP-2/MMP-9 and Wnt/ β -Catenin Signal Pathway. <i>Journal of Cancer</i> , 2021, 12, 467-473.	1.2	12
166	Cantharidin inhibits osteosarcoma proliferation and metastasis by directly targeting miR-214-3p/DKK3 axis to inactivate β -catenin nuclear translocation and LEF1 translation. <i>International Journal of Biological Sciences</i> , 2021, 17, 2504-2522.	2.6	20
167	Future Directions in the Treatment of Osteosarcoma. <i>Cells</i> , 2021, 10, 172.	1.8	102
169	MiR-183-5p Promotes Tumor Progression of Osteosarcoma and Predicts Poor Prognosis in Patients. <i>Cancer Management and Research</i> , 2021, Volume 13, 805-814.	0.9	5
170	MicroRNA-93 promotes the tumorigenesis of osteosarcoma by targeting TIMP2. <i>Bioscience Reports</i> , 2019, 39, .	1.1	11
172	Transcription Factor 21 (TCF21) rs12190287 Polymorphism is Associated with Osteosarcoma Risk and Outcomes in East Chinese Population. <i>Medical Science Monitor</i> , 2017, 23, 3185-3191.	0.5	16
173	Insulin-Like Growth Factor 1 (IGF1) Pathway Member Polymorphisms Are Associated with Risk and Prognosis of Chondrosarcoma. <i>Medical Science Monitor</i> , 2020, 26, e923853.	0.5	1
174	Exosome-mediated Hic-5 regulates proliferation and apoptosis of osteosarcoma via Wnt/ β -catenin signal pathway. <i>Aging</i> , 2020, 12, 23598-23608.	1.4	23
175	LINC00265 targets miR-382-5p to regulate SAT1, VAV3 and angiogenesis in osteosarcoma. <i>Aging</i> , 2020, 12, 20212-20225.	1.4	13
176	Notch-1 promotes the malignant progression of osteosarcoma through the activation of cell division cycle 20. <i>Aging</i> , 2021, 13, 2668-2680.	1.4	10
177	Whole-exome analysis in osteosarcoma to identify a personalized therapy. <i>Oncotarget</i> , 2017, 8, 80416-80428.	0.8	37
178	MicroRNA-944 targets vascular endothelial growth factor to inhibit cell proliferation and invasion in osteosarcoma. <i>Molecular Medicine Reports</i> , 2018, 18, 5221-5228.	1.1	7
179	miR-429 inhibits osteosarcoma progression by targeting HOXA9 through suppressing Wnt/ β -catenin signaling pathway. <i>Oncology Letters</i> , 2020, 20, 2447-2455.	0.8	14
180	Cell Differentiation Trajectory-Associated Molecular Classification of Osteosarcoma. <i>Genes</i> , 2021, 12, 1685.	1.0	6
181	MiR-149-5p: An Important miRNA Regulated by Competing Endogenous RNAs in Diverse Human Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 743077.	1.3	7
182	Novel circular RNA circATRNL1 accelerates the osteosarcoma aerobic glycolysis through targeting miR-409-3p/LDHA. <i>Bioengineered</i> , 2021, 12, 9965-9975.	1.4	11
183	Molecular profiling of osteosarcoma in children and adolescents from different age groups using a next-generation sequencing panel. <i>Cancer Genetics</i> , 2021, 258-259, 85-92.	0.2	5
184	Functional Genetic Single-Nucleotide Polymorphisms (SNPs) in Cyclin-Dependent Kinase Inhibitor 2A/B (CDKN2A/B) Locus Are Associated with Risk and Prognosis of Osteosarcoma in Chinese Populations. <i>Medical Science Monitor</i> , 2019, 25, 1307-1313.	0.5	5

#	ARTICLE	IF	CITATIONS
186	Biology of Osteosarcomas. , 2020, , 213-215.		0
187	Avenues of research in dietary interventions to target tumor metabolism in osteosarcoma. Journal of Translational Medicine, 2021, 19, 450.	1.8	10
189	Downregulation of the Proton-Activated Cl- Channel TMEM206 Inhibits Malignant Properties of Human Osteosarcoma Cells. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-16.	1.9	1
190	Long non-coding RNA NR2F1-AS1 facilitates the osteosarcoma cell malignant phenotype via the miR-485-5p/miR-218-5p/BIRC5 axis. Oncology Reports, 2020, 44, 1583-1595.	1.2	10
191	Long noncoding RNA NBAT1 negatively modulates growth and metastasis of osteosarcoma cells through suppression of miR-21. American Journal of Cancer Research, 2017, 7, 2009-2019.	1.4	22
192	Angiopoietin-like protein 2 is an important facilitator of tumor proliferation, metastasis, angiogenesis and glycolysis in osteosarcoma. American Journal of Translational Research (discontinued), 2019, 11, 6341-6355.	0.0	13
193	Effect of miR-135b inhibitor on biological characteristics of osteosarcoma cells through up-regulating PPM1A. International Journal of Clinical and Experimental Pathology, 2019, 12, 689-699.	0.5	4
194	ROCK2 mediates osteosarcoma progression and TRAIL resistance by modulating O-GlcNAc transferase degradation. American Journal of Cancer Research, 2020, 10, 781-798.	1.4	4
195	MARK2 enhances cisplatin resistance via PI3K/AKT/NF- κ B signaling pathway in osteosarcoma cells. American Journal of Translational Research (discontinued), 2020, 12, 1807-1823.	0.0	5
196	Gasdermin D expression and clinicopathologic outcome in primary osteosarcoma patients. International Journal of Clinical and Experimental Pathology, 2020, 13, 3149-3157.	0.5	4
197	A naturally derived small molecule PSM0537 targets the AF1Q-TCF4 interaction to suppress COX2 expression and inhibit cell proliferation and metastasis in osteosarcoma. American Journal of Cancer Research, 2021, 11, 2637-2653.	1.4	1
198	Preoperative prognostic nutritional index and systemic immune-inflammation index predict survival outcomes in osteosarcoma: A comparison between young and elderly patients. Journal of Surgical Oncology, 2022, 125, 754-765.	0.8	7
199	Extracellular Vesicles in Osteosarcoma: Antagonists or Therapeutic Agents?. International Journal of Molecular Sciences, 2021, 22, 12586.	1.8	12
201	Bioinformatics analysis of key pathways and genes in osteosarcoma development. Panminerva Medica, 2019, , .	0.2	1
202	Peptide-based semiconducting polymer nanoparticles for osteosarcoma-targeted NIR-II fluorescence/NIR-I photoacoustic dual-model imaging and photothermal/photodynamic therapies. Journal of Nanobiotechnology, 2022, 20, 44.	4.2	24
203	Emerging role of m6A modification in osteogenesis of stem cells. Journal of Bone and Mineral Metabolism, 2022, 40, 177-188.	1.3	6
204	Predictors of Chemotherapy Induced Adverse Events in Pediatric Osteosarcoma Patients. Asian Pacific Journal of Cancer Prevention, 2022, 23, 93-100.	0.5	3
205	Synchronous lung and multiple soft tissue metastases developed from osteosarcoma of tibia: a rare case report and genetic profile analysis. BMC Musculoskeletal Disorders, 2022, 23, 74.	0.8	2

#	ARTICLE	IF	CITATIONS
206	Predictive value of preoperative platelet-to-albumin ratio and apolipoprotein B-to-apolipoprotein A1 ratio for osteosarcoma in children and adolescents: a retrospective study of 118 cases. <i>BMC Cancer</i> , 2022, 22, 113.	1.1	7
207	Deficiency of TRDMT1 impairs exogenous RNA-based response and promotes retrotransposon activity during long-term culture of osteosarcoma cells. <i>Toxicology in Vitro</i> , 2022, 80, 105323.	1.1	6
208	N6-Methyladenosine-Related lncRNAs Are Potential Prognostic Biomarkers and Correlated With Tumor Immune Microenvironment in Osteosarcoma. <i>Frontiers in Genetics</i> , 2021, 12, 805607.	1.1	8
210	<i>Polygonum cuspidatum</i> inhibits the growth of osteosarcoma cells via impeding Akt/ERK/EGFR signaling pathways. <i>Bioengineered</i> , 2022, 13, 2992-3006.	1.4	6
211	miR-138 Reduces the Dysfunction of T Follicular Helper Cells in Osteosarcoma via the PI3K/Akt/mTOR Pathway by Targeting PDK1. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-12.	0.7	7
212	Immunoexpression of Ki67, p53 and cyclin D1 in osteosarcomas. <i>Romanian Journal of Morphology and Embryology</i> , 2021, 62, 743-750.	0.4	2
213	Osteosarcoma: A Surveillance, Epidemiology, and End Results program-based analysis from 1975 to 2017. <i>Cancer</i> , 2022, 128, 2107-2118.	2.0	57
214	COL5A2 Inhibits the TGF- β 2 and Wnt/ β 2-Catenin Signaling Pathways to Inhibit the Invasion and Metastasis of Osteosarcoma. <i>Frontiers in Oncology</i> , 2022, 12, 813809.	1.3	13
215	Comprehensive Analysis of a Zinc Finger Protein Gene-Based Signature with Regard to Prognosis and Tumor Immune Microenvironment in Osteosarcoma. <i>Frontiers in Genetics</i> , 2022, 13, 835014.	1.1	6
216	FAT1 and MSH2 Are Predictive Prognostic Markers for Chinese Osteosarcoma Patients Following Chemotherapeutic Treatment. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 885-895.	3.1	2
217	Recent and Ongoing Research into Metastatic Osteosarcoma Treatments. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3817.	1.8	44
218	CircRNA_0078767 promotes osteosarcoma progression by increasing CDK14 expression through sponging microRNA-330-3p. <i>Chemico-Biological Interactions</i> , 2022, 360, 109903.	1.7	9
219	Tumor Customized 2D Supramolecular Nanodiscs for Ultralong Tumor Retention and Precise Photothermal Therapy of Highly Heterogeneous Cancers. <i>Small</i> , 2022, 18, e2200179.	5.2	6
220	Ginsenoside Rg3 inhibits osteosarcoma progression by reducing circ_0003074 expression in a miR-516b-5p/KPNA4-dependent manner. <i>Journal of Orthopaedic Surgery and Research</i> , 2021, 16, 724.	0.9	7
221	Development and Validation of Ten-RNA Binding Protein Signature Predicts Overall Survival in Osteosarcoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 751842.	1.6	6
222	<i>MCAM</i> is associated with metastasis and poor prognosis in osteosarcoma by modulating tumor cell migration. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24214.	0.9	5
223	The Roles of KIFC1 in the Development of Osteosarcoma: Characterization of Potential Therapeutic Targets. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-10.	0.7	0
224	Sulfated alginate oligosaccharide exerts antitumor activity and autophagy induction by inactivating MEK1/ERK/mTOR signaling in a KSR1-dependent manner in osteosarcoma. <i>Oncogenesis</i> , 2022, 11, 16.	2.1	10

#	ARTICLE	IF	CITATIONS
225	Identification of a Solute Carrier Family-Based Signature for Predicting Overall Survival in Osteosarcoma. <i>Frontiers in Genetics</i> , 2022, 13, 849789.	1.1	6
228	ANGPTL4 negatively regulates the progression of osteosarcoma by remodeling branched-chain amino acid metabolism. <i>Cell Death Discovery</i> , 2022, 8, 225.	2.0	4
229	Identification and preliminary validation of a four-gene signature to predict metastasis and survival in osteosarcoma.. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 12264-12284.	0.0	0
230	USP1 inhibition suppresses the progression of osteosarcoma via destabilizing TAZ. <i>International Journal of Biological Sciences</i> , 2022, 18, 3122-3136.	2.6	11
231	Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes. <i>American Journal of Human Genetics</i> , 2022, 109, 1026-1037.	2.6	19
232	Regulated macrophage immune microenvironment in 3D printed scaffolds for bone tumor postoperative treatment. <i>Bioactive Materials</i> , 2023, 19, 474-485.	8.6	11
233	TRIM22 inhibits osteosarcoma progression through destabilizing NRF2 and thus activation of ROS/AMPK/mTOR/autophagy signaling. <i>Redox Biology</i> , 2022, 53, 102344.	3.9	43
234	Identification of novel natural inhibitors targeting AKT Serine/Threonine Kinase 1 (AKT1) by computational study. <i>Bioengineered</i> , 2022, 13, 12003-12020.	1.4	17
235	Biology-guided precision medicine in rare cancers: Lessons from sarcomas and neuroendocrine tumours. <i>Seminars in Cancer Biology</i> , 2022, 84, 228-241.	4.3	7
236	Exosomal CTCF Confers Cisplatin Resistance in Osteosarcoma by Promoting Autophagy via the IGF2-AS/miR-579-3p/MSH6 Axis. <i>Journal of Oncology</i> , 2022, 2022, 1-18.	0.6	5
237	Prognostic value of p16, p53, and pcna in sarcoma and an evaluation of immune infiltration. <i>Journal of Orthopaedic Surgery and Research</i> , 2022, 17, .	0.9	6
238	A Multicentre Clinical Study of Sarcoma Personalised Treatment Using Patient-Derived Tumour Xenografts. <i>Clinical Oncology</i> , 2023, 35, e48-e59.	0.6	5
239	PLCE1 is a poor prognostic marker and may promote immune escape from osteosarcoma by the CD70-CD27 signaling pathway. <i>Bosnian Journal of Basic Medical Sciences</i> , 2022, 22, 992-1004.	0.6	5
240	Precision Medicine Highlights Dysregulation of the CDK4/6 Cell Cycle Regulatory Pathway in Pediatric, Adolescents and Young Adult Sarcomas. <i>Cancers</i> , 2022, 14, 3611.	1.7	3
241	Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF- κ B signaling by down-regulation of miR-520c-3p. <i>Cancer Cell International</i> , 2022, 22, .	1.8	6
242	Integrated microfluidic-SERS for exosome biomarker profiling and osteosarcoma diagnosis. <i>Biosensors and Bioelectronics</i> , 2022, 217, 114709.	5.3	26
243	Generation and characterization of patient-derived xenografts from patients with osteosarcoma. <i>Tissue and Cell</i> , 2022, 79, 101911.	1.0	1
244	Enhancement of T Cell Infiltration via Tumor-Targeted Th9 Cell Delivery Improves the Efficacy of Antitumor Immunotherapy of Solid Tumors. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
245	N1-methyladenosine methylation-related metabolic genes signature and subtypes for predicting prognosis and immune microenvironment in osteosarcoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
246	Verification of Ferroptosis Subcluster-Associated Genes Related to Osteosarcoma and Exploration of Immune Targeted Therapy. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-27.	1.9	5
249	The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy. <i>Cancer Management and Research</i> , 0, Volume 14, 2945-2952.	0.9	1
250	Recent advances in hydrogels-based osteosarcoma therapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	4
251	Mediating effect assessment of ifosfamide on limb salvage rate in osteosarcoma: A study from a single center in China. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
252	Vessel state and immune infiltration of the angiogenesis subgroup and construction of a prediction model in osteosarcoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
253	Whole exome sequencing identified a novel POT1 variant as a candidate pathogenic allele underlying a Liâ€™Fraumeni-like family. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
254	Chitosan based photothermal scaffold fighting against bone tumor-related complications: Recurrence, infection, and defects. <i>Carbohydrate Polymers</i> , 2023, 300, 120264.	5.1	11
255	Current Status and Prospects of Targeted Therapy for Osteosarcoma. <i>Cells</i> , 2022, 11, 3507.	1.8	18
256	Ebastine exerts antitumor activity and induces autophagy by activating AMPK/ULK1 signaling in an IPMK-dependent manner in osteosarcoma. <i>International Journal of Biological Sciences</i> , 2023, 19, 537-551.	2.6	5
257	A recessive form of craniodiaphyseal dysplasia caused by a homozygous missense variant in SP7/Osterix. <i>Bone</i> , 2023, 167, 116633.	1.4	1
258	Silencing tumor-intrinsic HHLA2 potentiates the anti-tumoral effect of paclitaxel on MG63 cells: Another side of immune checkpoint. <i>Gene</i> , 2023, 855, 147086.	1.0	2
259	Enhancement of T cell infiltration via tumor-targeted Th9 cell delivery improves the efficacy of antitumor immunotherapy of solid tumors. <i>Bioactive Materials</i> , 2023, 23, 508-523.	8.6	1
260	Identification of genes contributing to cisplatin resistance in osteosarcoma cells. <i>FEBS Open Bio</i> , 2023, 13, 164-173.	1.0	0
261	Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment. <i>Nature Communications</i> , 2022, 13, .	5.8	20
262	Towards the Search for Potential Biomarkers in Osteosarcoma: State-of-the-Art and Translational Expectations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14939.	1.8	9
263	Transcriptomics and metabolomics reveal changes in the regulatory mechanisms of osteosarcoma under different culture methods in vitro. <i>BMC Medical Genomics</i> , 2022, 15, .	0.7	0
265	The Role of Tumor Microenvironment in Regulating the Plasticity of Osteosarcoma Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 16155.	1.8	7

#	ARTICLE	IF	CITATIONS
266	NIR Responsive Doxorubicin@Cu ₂ S Loaded Hollow Copper Ferrite @ Polydopamine for Synergistic Chemodynamic/Photothermal/Chemotherapy. <i>Small</i> , 2023, 19, .	5.2	13
267	One-pot synthesized nano-heterostructure with dual-modal catalytic ROS generation ability for high-metastatic orthotopic osteosarcoma therapy. <i>Carbon</i> , 2023, 204, 196-210.	5.4	5
268	Profilin 1 deficiency drives mitotic defects and reduces genome stability. <i>Communications Biology</i> , 2023, 6, .	2.0	2
269	Indoleamine 2,3- Dioxygenase: A Novel Immunotherapeutic Target for Osteosarcoma. <i>Journal of Cancer & Allied Specialties</i> , 2023, 9, .	0.1	0
270	Inhibition of Macropinocytosis Enhances the Sensitivity of Osteosarcoma Cells to Benzethonium Chloride. <i>Cancers</i> , 2023, 15, 961.	1.7	1
271	Pharmacogenetics of the Primary and Metastatic Osteosarcoma: Gene Expression Profile Associated with Outcome. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5607.	1.8	2
272	Clinicopathological significance of SOX9 and β -catenin expression in pre-neoadjuvant chemotherapy cases of osteosarcoma: molecular and immunohistochemical study. <i>Journal of Histotechnology</i> , 0, , 1-12.	0.2	0
273	Tumor-associated macrophages induce inflammation and drug resistance in a mechanically tunable engineered model of osteosarcoma. <i>Biomaterials</i> , 2023, 296, 122076.	5.7	4
274	ITGB3 promotes cisplatin resistance in osteosarcoma tumors. <i>Cancer Medicine</i> , 0, , .	1.3	2
275	Enhanced magnetothermal effect of high porous bioglass for both bone repair and antitumor therapy. <i>Materials and Design</i> , 2023, 227, 111754.	3.3	0
276	Osteosarcoma transcriptome data exploration reveals STC2 as a novel risk indicator in disease progression. <i>BMC Medical Genomics</i> , 2023, 16, .	0.7	1
277	APOC1 promotes the progression of osteosarcoma by binding to MTCH2. <i>Experimental and Therapeutic Medicine</i> , 2023, 25, .	0.8	3
278	Indirect bilirubin impairs invasion of osteosarcoma cells via inhibiting the PI3K/AKT/MMP-2 signaling pathway by suppressing intracellular ROS. <i>Journal of Bone Oncology</i> , 2023, 39, 100472.	1.0	2
279	MAPK-interacting kinases inhibition by eFT508 overcomes chemoresistance in preclinical model of osteosarcoma. <i>Human and Experimental Toxicology</i> , 2023, 42, 096032712311580.	1.1	1
280	Efficacy of Recombinant Human Endostatin plus Neoadjuvant Chemotherapy for Osteosarcoma and Its Influence on Serum VEGF and MMP-9 Levels. <i>Journal of Oncology</i> , 2023, 2023, 1-10.	0.6	0
281	PSKH1 affects proliferation and invasion of osteosarcoma cells via the p38/MAPK signaling pathway. <i>Oncology Letters</i> , 2023, 25, .	0.8	1
282	Transfer of exosomal microRNAs confers doxorubicin resistance in osteosarcoma cells. <i>Molecular Medicine Reports</i> , 2023, 27, .	1.1	3
283	Clinical-radiomics models based on plain X-rays for prediction of lung metastasis in patients with osteosarcoma. <i>BMC Medical Imaging</i> , 2023, 23, .	1.4	2

#	ARTICLE	IF	CITATIONS
284	Targeting RNA Polymerase I Transcription Activity in Osteosarcoma: Pre-Clinical Molecular and Animal Treatment Studies. <i>Biomedicines</i> , 2023, 11, 1133.	1.4	1
291	Novel insights into the METTL3-METTL14 complex in musculoskeletal diseases. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	2